-
Expression of SLC22A3 was significantly higher in colorectal cancer tissues than that in paired normal tissues. The phenotypes of proliferation, migration, invasion, cell cycle and apoptosis of colorectal cancer cell were significantly affected by SLC22A3 in vitro. Results revealed a novel susceptible locus, rs420038 in SLC22A3, which may be involved in colorectal cancer development and progression.
-
Study show that epigenetic alterations of SLC22A3 predispose susceptible individuals to increased risk of esophageal cancer.
-
The rs3088442 G>A variant of SLC22A3 acts as a protective allele and is associated with the clinical response to metformin. Overexpression of microRNA 147 is associated with a downward expression of the SLC22A3 gene in patients who have type 2 diabetes.
-
The rs2048327 single nucleotide polymorphism of the SLC22A3 gene was significantly associated with lipoprotein(a) as well as with cardiovascular disease events in familial hypercholesterolemia subjects
-
Data show that the common variation in the solute carrier family 22 member 3 (SLC22A3) gene is unlikely to significantly contribute to pancreatic cancer risk, and the rs2504938 single nucleotide polymorphism (SNP) in SLC22A3 significantly associates with an unfavorable prognosis of pancreatic cancer patients.
-
SNPs in SLC22A3 and H3F3B may influence lipid levels through altering the expression of local genes.
-
A-to-I RNA editing of SLC22A3 contributes to the early development and progression of familial esophageal squamous cell carcinoma in high-risk individuals.
-
our study suggests that several PHACTR1 and SLC22A3 gene polymorphisms may exert a protective effect against the CAD in the Chinese Han male population.
-
SLC22A3 deletion is associated with motor speech disorders, and language delays.
-
may be a regulator of the concentration of norepinephrine in adipose tissue.
-
the rs3088442G>A variant as a genetic marker may potentially assist in the identification of individuals at an increased risk of T2D.
-
The genotype of rs3088442 within the SLC22A3-LPAL2-LPA gene cluster may contribute to regulation of plasma Lp(a) levels and possibly to the severity of coronary artery disease in a Chinese Han population.
-
Findings suggest specific involvement of each organic cation transporters (OCT1-3) in drug transportation.
-
Findings suggest that OCT3 plays an important role in the absorption and elimination of metformin and that the transporter is a critical determinant of metformin bioavailability, clearance, and pharmacologic action.
-
The markers of EMT were detected by using Western blot.
-
Findings suggest a negative feedback mechanism against inflammatory response by which solute carrier family 22 member 3 (SLC22A3) variant rs3088442 G-->A decreased the risk of coronary heart disease (CHD).
-
Cultured astroctye line 1321N1 and primary human astrocytes transport monoamines partly through OCT3.
-
There was no association between rs7758229 in 6q26-q27/SLC22A3 and the risk of colorectal cancer in a Chinese population.
-
Decreasing expression of OCT3 and MATE1 in human placenta indicates these transporters may play a role in fetal protection preferentially at earlier stages of gestation.
-
Our studies demonstrate that genetic polymorphisms in the proximal promoter region of OCT3 alter the transcription rate of the gene and may be associated with altered expression levels of OCT3 in human liver.